Logos Global Management »

Acelyrin shares owned by Logos Global Management

Quarter-by-quarter ownership of Acelyrin (SLRN) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Acelyrin

Tip: Access up to 7 years of quarterly data

All positions including Acelyrin held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acelyrin by Logos Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $9.3M 1.3M 7.46

More positions owned by Logos Global Management

Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Sarepta Therapeutics Call Option (SRPT)
Ideaya Biosciences (IDYA)
Argenx Se Sponsored Adr (ARGX)
Olema Pharmaceuticals (OLMA)
Immunovant (IMVT)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Rayzebio
Ambrx Biopharma
Karuna Therapeutics Ord
Immunocore Hldgs Ads (IMCR)
Dyne Therapeutics (DYN)
Morphosys Sponsored Ads Call Option (MOR)

View all positions for Logos Global Management

Top funds holding Acelyrin

Citadel Advisors
Vanguard Group
Opaleye Management
OrbiMed Advisors
venBio Partners
Jpmorgan Chase & Co
Artal Group
Samsara BioCapital
Ikarian Capital
Blue Owl Capital Holdings
Henderson Group
Decheng Capital
Logos Global Management
Kynam Capital Management
Goldman Sachs Group

View all funds holding Acelyrin